From the Ionis Pharmaceuticals, Inc. financial results for the second quarter of 2021 and recent business achievements:
“Since our last quarterly update, we continued to execute on our strategic objectives to prepare for multiple commercial launches, expand our drug delivery capabilities and advance new products towards the market. Looking ahead, we expect data from multiple pipeline programs, including additional data supporting the potential for our IONIS-PKK-LRx program to change the standard of care for patients with HAE”, says Brett P. Monia, Ph.D., CEO of Ionis.
(Source: Ionis)
